Could a common supplement slow Alzheimer's? new trial aims to find out

NCT ID NCT06797817

Not yet recruiting Disease control Sponsor: Universidad de Almeria Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial tests whether a daily supplement called tributyrin can slow cognitive decline in people with mild Alzheimer's disease. Over 12 weeks, 156 participants will take either tributyrin or a placebo. Researchers will measure changes in memory, thinking, gut bacteria, and inflammation markers to see if boosting butyrate levels helps protect the brain.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tributyrin (a dietary supplement that boosts butyrate levels)
What this could lead to: If it works, this could point toward a simple, safe supplement to slow cognitive decline in early Alzheimer's disease.
What could go wrong: This is still an early-stage Phase 3 trial with only 156 participants. The supplement may not improve cognition or gut health, and results may not apply to everyone with Alzheimer's.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE (AD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease Cognitive Dysfunction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER DISEASE (AD)

Contacts and locations

Locations

Universidad de Almería

Almería, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.